Semaglutide — The Next Structural Opportunity for Indian Pharma?
With semaglutide’s key patent expected to expire in India around March 2026 and global pricing pressure building, Indian pharma companies may get a structural entry opportunity into the GLP-1 segment. However, complex peptide manufacturing and regulatory barriers mean this is a medium-term execution story, not an immediate earnings trigger.
CONTINUE READING...